Illumina Enhances TruSight Oncology 500 for Faster Tumor Profiling and HRD Detection

Illumina has launched the next generation of its flagship cancer research assay, TruSight Oncology 500 v2, which enables comprehensive genomic profiling with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input. This enhanced assay is designed to facilitate therapy selection research and expand access to tumor profiling and cancer therapy research.

Illumina Inc. (NASDAQ: ILMN) has introduced the next generation of its TruSight Oncology 500 v2 assay, a significant advancement in comprehensive genomic profiling (CGP) for cancer research. The updated assay includes built-in homologous recombination deficiency (HRD) biomarker detection, faster turnaround times, and reduced tissue sample requirements, addressing key challenges in cancer therapy research.

The TruSight Oncology 500 v2 offers several enhancements over its predecessor. It incorporates HRD status analysis using Myriad Genetics' gold-standard Genomic Instability Scoring algorithm, expanding research into the value of the HRD biomarker in various cancer types. This integration is particularly beneficial for identifying tumors with defects in DNA repair mechanisms, which can inform therapy selection research, especially for PARP inhibitors [1].

The streamlined workflow of TSO 500 v2 reduces turnaround time and hands-on time, making it more efficient for laboratories. The redesigned kit includes 50% less packaging and 70% fewer tubes, with color-coded tubing for easier tracking. These optimizations not only improve laboratory economics but also reduce potential error rates [1].

Early access customers have praised the improvements. Weiyi Chen, PhD, technical director at siParadigm Diagnostic Informatics, noted that TSO 500 v2 offers improved accuracy and faster turnaround times compared to their current solution. Conxi Lázaro, PhD, lab director at the Catalan Institute of Oncology, highlighted the enhanced sustainability features and simplified user experience [1].

Illumina's investment in the TSO 500 v2 reflects its commitment to serving customers with high-quality solutions. The company's oncology portfolio includes both research-use-only and in vitro diagnostic solutions, addressing a broad range of biomarker profiling needs. Through partnerships like the one with Pillar BioSciences, Illumina continues to expand its offerings in the precision oncology market [1].

The launch of TSO 500 v2 positions Illumina as a leader in CGP, addressing critical pain points in cancer research. The integration of HRD biomarker detection, faster workflows, and reduced sample requirements strengthen the company's position in the competitive precision oncology market [2].

References:
[1] https://www.prnewswire.com/news-releases/illumina-enhances-flagship-assay-to-accelerate-access-to-comprehensive-tumor-profiling-302517047.html
[2] https://www.stocktitan.net/news/ILMN/illumina-enhances-flagship-assay-to-accelerate-access-to-xz870wif1kae.html